Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTICORT vs VOSOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.
Corticosteroid-responsive dermatoses (e.g., eczema, psoriasis, contact dermatitis),Off-label: atopic dermatitis, lichen planus, discoid lupus erythematosus
Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.
Hepatic metabolism via CYP3A4; inactive metabolites excreted renally and biliary.
Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.
90% bound to albumin and corticosteroid-binding globulin
90–95%, primarily to albumin.
1.2-1.5 L/kg; indicates extensive tissue distribution
Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.
Oral: 80-90%; IM: 100%
Otic: 80–90% (local absorption with minimal systemic).
No dose adjustment necessary for acute use; for chronic therapy in severe renal impairment (e GFR <30 m L/min/1.73 m2), consider dose reduction by 50% to minimize mineralocorticoid effects.
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75% due to reduced clearance.
No dosage adjustment required for hepatic impairment.
0.05-2 mg/kg/day orally divided every 6-8 hours, not to exceed 80 mg/day; adjust based on response and severity.
Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.
Initiate at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, glucose intolerance, and immunosuppression; monitor for adverse effects.
No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.
None
None
HPA axis suppression with prolonged use or large surface area,Local irritation and skin atrophy,Systemic absorption with occlusive dressings,Potential for rebound effects after discontinuation
For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane
Known hypersensitivity to components,Untreated bacterial/fungal infections,Viral skin infections (e.g., herpes simplex, varicella),Perioral dermatitis, rosacea
Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy
No clinically significant food interactions. Alcohol may increase systemic absorption if tympanic membrane is perforated, but generally avoid alcohol-based ear drops if perforation suspected.
No known food interactions. Alcohol consumption is not restricted.
First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnios with chronic use. Avoid use unless maternal benefit outweighs risks.
VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.
Prednisone enters breast milk at low levels (M/P ratio ~0.1-0.3). At maternal doses ≤20 mg/day, the infant dose is <10% of maternal weight-adjusted dose. Consider risk of adrenal suppression in infant with high-dose, long-term therapy. AAP rates as compatible with breastfeeding.
No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.
No empirical dose adjustment required; however, pharmacokinetic changes (increased Vd, hepatic metabolism) may reduce efficacy. Doses may need to be increased by 20-30% in third trimester if disease activity increases. Taper to lowest effective dose.
No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.
ACTICORT (hydrocortisone/neomycin/polymyxin B) is a topical combination used for inflammatory ear conditions. Avoid prolonged use (>10 days) to prevent sensitization and overgrowth of non-susceptible organisms. Tympanic membrane perforation is a contraindication due to ototoxicity risk. Use the otic solution not the ophthalmic suspension for ear infections.
VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.
Instill drops while lying down with affected ear upward, then remain in position for 5 minutes.,Do not touch dropper to ear or any surface to avoid contamination.,Complete full course even if symptoms improve; do not use longer than prescribed.,Report worsening redness, swelling, or hearing loss immediately.,Avoid getting water in ear during treatment; use a cotton ball soaked in petroleum jelly to protect ear when showering.
Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTICORT vs VOSOL HC, answered by our medical review team.
ACTICORT is a Corticosteroid that works by Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.. VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTICORT and VOSOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTICORT is: 5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.. The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTICORT and VOSOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTICORT is classified as Category C. First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnio. VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.